Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics.
Autor: | Addison ML; University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, College of Medicine & Veterinary Medicine, The University of Edinburgh, Scotland, United Kingdom (M.L.A., P.R., D.J.W.)., Ranasinghe P; University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, College of Medicine & Veterinary Medicine, The University of Edinburgh, Scotland, United Kingdom (M.L.A., P.R., D.J.W.).; Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka (P.R.)., Webb DJ; University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, College of Medicine & Veterinary Medicine, The University of Edinburgh, Scotland, United Kingdom (M.L.A., P.R., D.J.W.). |
---|---|
Jazyk: | angličtina |
Zdroj: | Hypertension (Dallas, Tex. : 1979) [Hypertension] 2023 Nov; Vol. 80 (11), pp. 2243-2254. Date of Electronic Publication: 2023 Sep 14. |
DOI: | 10.1161/HYPERTENSIONAHA.122.19430 |
Abstrakt: | Hypertension remains the leading cause of cardiovascular disease and premature death globally, affecting half of US adults. A high proportion of hypertensive patients exhibit uncontrolled blood pressure (BP), associated with poor adherence, linked to pill burden and adverse effects. Novel pharmacological strategies are urgently needed to improve BP control. Dysregulation of the renin-angiotensin system increases BP through its primary effector, Ang II (angiotensin II), which results in tissue remodeling and end-organ damage. Silencing liver angiotensinogen (the sole source of Ang II) has been achieved using novel RNA therapeutics, including the antisense oligonucleotide, IONIS-AGT (angiotensinogen)-LR Competing Interests: Disclosures Dr Webb has received nonpersonal support for research and consultancy from AbbVie, Actelion, AstraZeneca, Idorsia, Johnson & Johnson, and Novartis. Dr Webb has received funding for research in hypertension from the British Heart Foundation. University/British Heart Foundation Center for Cardiovascular Science received funding from Alnylam Pharmaceuticals for phase I trials with zilebesiran. The other authors report no conflicts. |
Databáze: | MEDLINE |
Externí odkaz: |